SARS-CoV-2 protein subunit recombinant vaccine

BIOLOGICAL4 trials

Sponsors

PT Bio Farma

Conditions

COVID-19Covid19Vaccine Adverse ReactionVaccine Reaction

Phase 1

Safety and Immunogenicity of SARS-CoV-2 Protein Subunit Recombinant Vaccine

CompletedNCT05067894

PT Bio FarmaCovid19

Start: 2021-12-10End: 2022-08-06Updated: 2022-08-09

Safety and Immunogenicity Study of COVID-19 Protein Subunit Recombinant Vaccine Adjuvanted With Alum+CpG 1018

CompletedNCT05228613

PT Bio FarmaCOVID-19

Start: 2022-02-16End: 2023-01-24Updated: 2023-02-27

Phase 2

Safety and Immunogenicity Study of COVID-19 Protein Subunit Recombinant Vaccine

CompletedNCT05313035

PT Bio FarmaCOVID-19

Start: 2022-04-13End: 2023-02-28Updated: 2023-04-13

Phase 3

Safety and Immunogenicity of SARS-CoV-2 Protein Subunit Recombinant Vaccine in Healthy Children

CompletedNCT05546502

PT Bio FarmaVaccine Adverse Reaction, Vaccine Reaction

Start: 2022-10-09End: 2024-01-31Updated: 2025-06-03